Inovio Pharmaceuticals

98 articles with Inovio Pharmaceuticals

• Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia

  8/19/2019

  Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has completed enrollment in the company's open-label, 24 patient, Phase 2 trial with its lead immunotherapy product VGX-3100 in patients with precancerous lesions of the anus, i.e. anal high-grade squamous intraepithelial lesions (anal HSIL, aka anal intraepithelial neoplasia)

• Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results

  8/8/2019

  Inovio Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2019.

• Inovio Closes $15 Million Private Placement of Convertible Bonds to Institutional Investors in Korea

  8/6/2019

  Inovio Intends to Pursue Secondary Listing on Korea Exchange (KRX)

• Inovio Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8, 2019

  7/30/2019

  Following the release, the company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the second quarter 2019.

• Inovio's Positive First-in-Human MERS Vaccine Results Published in The Lancet Infectious Diseases

  7/25/2019

  This latest publication underscores the potential for rapid deployment of Inovio's DNA vaccines.

• 

  Inovio, Amneal Slash Workforces as Both Companies Undergo Realignments

  7/17/2019

  More than 600 employees will lose their jobs as the companies reshape their corporate strategies.

• Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates

  7/16/2019

  Inovio Pharmaceuticals, Inc. announced that it has sharpened its corporate strategy to focus on the commercial development of its late-stage HPV assets and reallocate capital to develop fast-to-market product candidates.

• Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

  7/10/2019

  This is the First-in-Human Implementation for Geneos Therapeutics' Exquisitely Personalized Immunotherapies for Cancer (GT-EPIC) Platform Clinical collaboration with Washington University

• Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN)

  7/8/2019

   Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN).

• Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer

  6/26/2019

  If approved, VGX-3100 would be the first immunotherapy and non-surgical alternative for women with late-stage cervical dysplasia.

• Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device

  6/10/2019

  In addition to the development of CELLECTRA 3PSP, the new award will fund the investigation of DNA vaccines developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) using the new device.

• Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial

  5/21/2019

  Subjects dosed in First-in-Human study of INO-4500 funded by the Coalition for Epidemic Preparedness Innovations

• QIAGEN and Inovio Collaborate to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions

  5/16/2019

  Liquid biopsy-based Precision Medicine test to guide patient selection for Inovio’s VGX-3100

• Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus

  5/15/2019

  Inovio Pharmaceuticals Inc. and Plumbline Life Sciences announced a collaboration to co-develop a novel animal health vaccine for African swine fever virus.

• Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results

  5/9/2019

  Inovio Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2019.

• Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100

  5/6/2019

  The procedure of certification of quality and non-clinical data involves an assessment of the available data in view of future registration and the related European Scientific Data Requirements, not including any clinical data or benefit-risk assessment.

• Inovio Pharmaceuticals to Report First Quarter 2019 Financial Results on May 9, 2019

  5/1/2019

  Following the release, the Company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the first quarter 2019.

• Inovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers (dBiTEs™) in a Peer-reviewed Journal

  4/18/2019

  Data demonstrates tumor-clearing ability of Inovio's dBiTE

• Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress

  4/17/2019

  The Vaccine Industry Excellence Awards honor outstanding vaccine and immunotherapy advancements and achievements across the worldwide industry as judged by a panel of global biotech industry stakeholders.

• Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development

  4/8/2019

  The milestone achievement for this multi-indication trial is the third MEDI0457-related Phase 2 milestone from AstraZeneca; two previous milestone payments resulted from initiating Phase 2 combination trials targeting head and neck and cervical cancers. Financial arrangements were not disclosed.